Inclusion Criteria:

        A patient will be eligible for inclusion in this study only if all of the following
        criteria are met:

          1. Patients must have a histologically confirmed diagnosis of Ewing's sarcoma, PEComa,
             epithelioid sarcoma, desmoid tumor, chordoma, non-small cell lung cancer, small cell
             lung cancer, urethelial carcinoma, melanoma, renal cell carcinoma, squamous cell
             carcinoma of head and neck, hepatocellular carcinoma, classical Hodgkin's lymphoma,
             MSI-H/dMMR metastatic colorectal cancer, and tumors with genetic mutations sensitive
             to mTOR inhibitors, that is either metastatic or locally advanced and for which
             surgery is not a recommended option.

          2. Patients must have one or more measurable target lesions by CT scan or MRI. Measurable
             disease by RECIST v1.1.

          3. Patients must not have been previously treated with a PD-1 inhibitor in combination
             with an mTOR inhibitor.

          4. Prior treatment (investigational or other), chemotherapy, radiotherapy, surgery, or
             other therapeutic agents (except immunotherapy and mTOR inhibitors) is allowed, if
             completed after 5 half-lives or ≥28 days prior to enrollment, whichever is shorter.

          5. Eligible patients, 12 years or older, with Eastern Cooperative Oncology Group (ECOG)
             performance status 0 or 1.

          6. Patients must have the following blood chemistry levels at screening (obtained ≤14
             days prior to enrollment (local laboratory):

               1. total bilirubin ≤1.5 x upper limit of normal (ULN) mg/dl

               2. AST ≤2.5 x ULN (≤5 x ULN if attributable to liver metastases)

               3. serum creatinine ≤1.5 x ULN

          7. Adequate biological parameters as demonstrated by the following blood counts at
             screening (obtained ≤14 days prior to enrollment, local laboratory):

               1. Absolute neutrophil count (ANC) ≥1.5 × 109/L;

               2. Platelet count ≥100,000/mm3 (100 × 109/L);

               3. Hemoglobin ≥9 g/dL.

          8. Serum triglyceride <300 mg/dL; serum cholesterol < 350 mg/dL.

          9. Male or non-pregnant and non-breast feeding female:

             Females of child-bearing potential must agree to use effective contraception without
             interruption from 28 days xprior to starting IP and while on study medication and have
             a negative serum pregnancy test (β -hCG) result at screening and agree to ongoing
             pregnancy testing during the course of the study, and after the end of study
             treatment. A second form of birth control is required even if she has had a tubal
             ligation.

             Male patients must practice abstinence or agree to use a condom during sexual contact
             with a pregnant female or a female of childbearing potential while participating in
             the study. A second form of birth control is required even if he has undergone a
             successful vasectomy.

         10. Life expectancy of >3 months, as determined by the investigator.

         11. Ability to understand and sign informed consent.

         12. Willingness and ability to comply with scheduled visits, laboratory tests, and other
             study procedures.

        Exclusion Criteria:

        A patient will not be eligible for inclusion in this study if any of the following criteria
        apply:

          1. Concurrent or prior immunotherapy with a PD-1 inhibitor in combination with an mTOr
             inhibitor.

          2. Known active uncontrolled or symptomatic central nervous system (CNS) metastases. A
             patient with controlled and asymptomatic CNS metastases may participate in this study.
             As such, the patient must have completed any prior treatment for CNS metastases ≥28
             days (including radiotherapy and/or surgery) prior to start of treatment in this study
             and should not be receiving chronic corticosteroid therapy for the CNS metastases.

          3. Active gastrointestinal bleeding.

          4. Pre-existing thyroid abnormality is allowed provided thyroid function can be
             controlled with medication.

          5. Uncontrolled serious medical or psychiatric illness. Patients with a "currently
             active" second malignancy other than non-melanoma skin cancers, carcinoma in situ of
             the cervix, resected incidental prostate cancer (staged pT2 with Gleason Score ≤ 6 and
             postoperative PSA <0.5 ng/mL), or other adequately treated carcinoma-in-situ are
             ineligible. Patients are not considered to have a "currently active" malignancy if
             they have completed therapy and are free of disease for ≥1 year).

          6. Liver-directed therapy within 2 months of enrollment. Prior treatment with
             radiotherapy (including radio-labeled spheres and/or cyberknife, hepatic arterial
             embolization (with or without chemotherapy) or cyrotherapy/ablation) is allowed if
             these therapies did not affect the areas of measurable disease being used for this
             protocol.

          7. Recent infection requiring systemic anti-infective treatment that was completed ≤14
             days prior to enrollment (with the exception of uncomplicated urinary tract infection
             or upper respiratory tract infection).

          8. Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy.

          9. Unstable coronary artery disease or myocardial infarction during preceding 6 months.

         10. Receiving any concomitant antitumor therapy.

         11. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary
             hypertension.

         12. Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving
             the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with
             narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride,
             dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to
             receiving the first dose of ABI-009.

         13. Known Human Immunodeficiency Virus (HIV).

         14. Active Hepatitis B or Hepatitis C.

         15. Non-oncology vaccine therapy used for prevention of infectious disease within 4 weeks
             of trial enrollment

         16. Autoimmune disease including rheumatoid arthritis, systemic progressive sclerosis
             (scleroderma), systemic lupus erythematosus, autoimmune vasculitis and motor
             neuropathy considered to be of autoimmune origin (e.g. Guillain-Barre Syndrome)

         17. Systemic immunosuppression, including HIV positive status with or without AIDS

         18. Skin rash (psoriasis, eczema) affecting > 25% body surface area

         19. Inflammatory bowel disease (Crohn's or ulcerative colitis)

         20. Ongoing or uncontrolled diarrhea within 4 weeks of trial enrollment

         21. Recent history of acute diverticulitis, intraabdominal abscess or gastrointestinal
             obstruction within 6 months of trial enrollment, which are known risk factors for
             bowel perforation

         22. Current, active or previous history of heavy alcohol abuse

         23. Pituitary endocrinopathy

         24. Adrenal insufficiency or excess